Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Krystal Biotech, Inc. KRYS
$88.03
-$2.22 (-2.52%)
На 18:00, 12 мая 2023
+51.08%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
2331486032.00000000
-
week52high
93.00
-
week52low
47.67
-
Revenue
0
-
P/E TTM
-16
-
Beta
0.84809600
-
EPS
-5.42000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Neutral | Buy | 25 авг 2022 г. |
| Chardan Capital | Buy | Buy | 09 авг 2022 г. |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| Goldman Sachs | Buy | Buy | 01 мар 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 28 февр 2022 г. |
| Chardan Capital | Buy | Buy | 08 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 07 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Krishnan Krish S | D | 1677263 | 804 | 18 янв 2023 г. |
| Krishnan Krish S | D | 1678067 | 2048 | 18 янв 2023 г. |
| Krishnan Krish S | D | 1738688 | 803 | 18 янв 2023 г. |
| Krishnan Krish S | D | 1739491 | 2048 | 18 янв 2023 г. |
| Krishnan Suma | D | 1738688 | 803 | 18 янв 2023 г. |
| Krishnan Suma | D | 1739491 | 2048 | 18 янв 2023 г. |
| Krishnan Suma | D | 1677263 | 804 | 18 янв 2023 г. |
| Krishnan Suma | D | 1678067 | 2048 | 18 янв 2023 г. |
| Krishnan Krish S | D | 1680115 | 345 | 17 янв 2023 г. |
| Krishnan Krish S | D | 1680460 | 1186 | 17 янв 2023 г. |
Новостная лента
Krystal Biotech: 2 Potential Regulatory Approvals To Carry It Forward
Seeking Alpha
08 мая 2023 г. в 14:27
Krystal Biotech, Inc. has a PDUFA date of May 19, 2023, established for the FDA to review B-VEC for potential U.S. marketing approval to treat patients with Dystrophic Epidermolysis Bullosa. There is potential European approval of B-VEC for the treatment of patients with Dystrophic Epidermolysis Bullosa expected in early 2024.
Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting
GlobeNewsWire
13 апр 2023 г. в 07:00
Clinical data on the compassionate use of B-VEC to treat a RDEB patient, with recurrent cicatrizing conjunctivitis that leads to conjunctival scarring, at the Bascom Palmer Eye Institute
Krystal Biotech: Reached My Price Target, Waiting For A Drop
Seeking Alpha
20 янв 2023 г. в 17:20
I sold out of Krystal Biotech stock after it hit my 65% profit price target. I am looking for another opportunity to enter.
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
InvestorPlace
18 дек 2022 г. в 18:21
Some of the hottest biotech stocks are safe and recession-proof. After all, we can't stop people from aging – at least, not yet.
Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference
GlobeNewsWire
23 ноя 2022 г. в 07:00
PITTSBURGH, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the Evercore ISI 5th Annual HealthCONx Conference, which is taking place virtually from November 29-December 1.